Abstract:Abstract Fibroblast activation protein has emerged as an attractive biomarker for the imaging and therapyof ~90% of human epithelial cancers due to its expression on cancer associated fibroblasts (CAFs), but not on fibroblasts in healthy tissues. Not surprisingly, several small molecules and peptide-based radioligands that target FAP have been introduced into human clinical trials, but preclinical and clinical data suggest that these radioligand therapies suffer from inadequate tumor uptake, short tumor residence times, or unwanted uptake in the healthy tissues. Hence, there remains an unmet need for development of new FAP-targeted radioligands with improved therapeutic properties. For this purpose, we have designed and synthesized a higher affinity and specificity FAP-targetingligand (FAP8) and linked this ligand via a PEG spacer to both a well-known metal chelator (DOTA)and a 4(-iodo)-phenyl butyric acid pharmacokinetic extender to yield the trifunctional conjugate, FAP8-IP-DOTA. Binding affinity and FAP specificity studies reveal that FAP8-IP-DOTA exhibits high affinity and selectivity for FAP (IC50 = 1.6 nM) relative to its ubiquitous homologs’ prolyloligopeptidase (IC50 = 16.5 nM) and dipeptidyl peptidase-IV (IC50 = 865.0 nM). Moreover, 177Luand 111In radiolabeled forms of the conjugate were found to bind a FAP-transduced cell line (HEK-FAP) with a Kd = 3.0 ± 2 nM, and this binding was completely suppressed upon co-incubation with unlabeled conjugate, i.e., further confirming FAP’s specificity. SPECT/CT imaging studies following intravenous injection of 111In labelled FAP8-IP-DOTA into mice expressing HT29, MDA-MB-231, KB or 4T1 tumors then demonstrated high tumor uptake and remarkably prolonged tumor retention of >8 days. Biodistribution studies of the 177Lu labelledFAP8-IP-DOTA conjugate in mice implanted with either FAP-negative 4T1 tumor cells or FAP-transduced HEK tumor cells at different time points further revealed declining tumor radioactivity from 12.0 to 2.0 % ID/g and 21.0 to 12.0 %ID/g between 1h and 168h post injection, respectively. Importantly, uptake of the same conjugate in the healthy tissues was minimal over this time course, with most radioactivity clearing rapidly. Comparative dosimetry analyses showed tumor: healthy tissues ratios of >5-fold for all major organs. Finally, analysis of tumor inhibiting activity demonstrated that 177Lu-FAP8-IP-DOTA suppressed tumor growth between 60% and 100% in all xenograft models tested (HT29, MDA-MB-231, KB and 4T1), with remarkably improved overall survival rates compared to untreated groups. Based on these promising results, we suggest that FAP8-IP-DOTA warrants further evaluation for possible translation into human clinical trials. Citation Format: Ramesh Mukkamala, Lindemann D. Spencer, Carlson J. Daniel, Pooja Tudi, Miller Nicholas Kaine, Autumn Horner, Srinivasarao Madduri, Philip S. Low. Novel fibroblast activation protein targeting radioligand for imaging and radiotherapy of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1119.

Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors

An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy

Molecular Evolution of Multivalent OncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor Retention

Abstract 1119: Novel fibroblast activation protein targeting radioligand for imaging and radiotherapy of solid tumors

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications

Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study

Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [68Ga]ga-Fapi-fuscc-ii.

Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA

Synthesis and preclinical evaluation of novel 18 F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts

Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

68Ga/177Lu-Labeled Theranostic Pair for Targeting Fibroblast Activation Protein with Improved Tumor Uptake and Retention

Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy

Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade

Radiosynthesis, preclinical evaluation and pilot clinical PET imaging study of a 18F-labeled tracer targeting fibroblast activation protein

225Ac-Labeled Antibody for Fibroblast Activation Protein-Targeted Alpha Therapy

High Affinity and FAP-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake for FAP Inhibitors

99mTc-labeled FAPI compounds for cancer and inflammation: from radiochemistry to the first clinical applications